Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? - Wikidata - awgldk - TriplyDB

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

http://www.wikidata.org/entity/Q48238873

about

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

http://www.wikidata.org/entity/Q48238873

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

@en

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

@nl

type

label

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

@en

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

@nl

prefLabel

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

@en

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

@nl

P1433

Q48238873-16C29E0B-563C-492E-839E-EB03CF174C17

P1476

Q48238873-C7AE8CEB-ED70-4DAD-B16F-102993E91799

P2093

Q48238873-15808A27-CEED-484E-B95D-C0F42D963EC1

Q48238873-1644CA39-2EAE-48D4-8E34-2AB46E2DEA3D

Q48238873-203898B1-26E5-4CDE-BB54-34C5C07B42B4

Q48238873-235CBFAF-D545-4226-A229-5F0A4EAB8238

Q48238873-5405ACF2-F6C2-4615-A225-8B5333A95C50

Q48238873-6D3FF4E7-4D50-4CE4-97E6-DED203E3EAA2

Q48238873-7C0B9AF4-B7E3-42BF-B0D0-88BB7E14670C

Q48238873-BA18141C-296D-463F-99DF-0D2F69877211

Q48238873-FA0EF195-13B5-4350-BBCA-051DEC0724FF

P2860

Q48238873-01E3587D-BF92-42DD-BAED-D4CBDEF5347E

Q48238873-1BD0CBA7-B1DC-4544-9284-3DD91F710ABE

Q48238873-1BE5552D-FCD1-478A-A000-93B45A461CE9

Q48238873-22FBDAEA-9802-4156-881A-56AF92369AD7

Q48238873-24958BD7-5B72-4ED7-BA3F-C35A0CDFD4B4

Q48238873-2739A734-E7C2-4388-8651-55EC8C45AF3A

Q48238873-2FCFC46A-346A-4594-8FFC-218E6B32AAB1

Q48238873-352EC058-7DB7-4AED-8EBA-11718D195B80

Q48238873-3769BBAC-4E19-40CC-901B-57B7FECAB777

Q48238873-3DE45B60-37E1-4CC7-BA2D-5D169325C350

P2888

Q48238873-F423DA14-B6ED-4578-A7EF-614B94A191F3

P304

Q48238873-F505740C-CBB3-4511-A64C-C6D50433157D

P31

Q48238873-4735AD87-CF15-4BF0-A61A-FE57F2AB146B

P356

Q48238873-B7E15048-EA51-4CAC-A5B5-0D358740F261

P407

Q48238873-32888A31-A446-4BA7-999E-8C90ED2C8F13

P433

Q48238873-5A53F559-FEAE-4BE4-ABD5-67BCB239BFD4

P478

Q48238873-6DC78873-C16B-4332-AF31-1A8E4A998B15

P50

Q48238873-6AE15B18-75CC-428F-9E3B-F6B6B2F8F164

P577

Q48238873-7C098EE6-B105-4B63-A3C5-81D107AB8518

P698

Q48238873-437B9FB7-AD8E-47F5-871E-AC1A16B9C635

P921

Q48238873-6B0DFC84-BC04-4405-9EFF-3B16E20D5653

P356

S00330-017-5146-8

P1433

European Radiology

P1476

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

@en

P2093

Di Dong

http://www.w3.org/2001/XMLSchema#string

Hongmei Zhang

http://www.w3.org/2001/XMLSchema#string

Jianming Ying

http://www.w3.org/2001/XMLSchema#string

Lei Yang

http://www.w3.org/2001/XMLSchema#string

Mengjie Fang

http://www.w3.org/2001/XMLSchema#string

Xinming Zhao

http://www.w3.org/2001/XMLSchema#string

Yali Zang

http://www.w3.org/2001/XMLSchema#string

Yongbei Zhu

http://www.w3.org/2001/XMLSchema#string

Zhenyu Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Dermatologist-level classification of skin cancer with deep neural networks

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Radiomics: Images Are More than Pictures, They Are Data.

(18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer.

P2888

s00330-017-5146-8

P304

2058-2067

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00330-017-5146-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29335867

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer